<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126099">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01951274</url>
  </required_header>
  <id_info>
    <org_study_id>TCP 101</org_study_id>
    <nct_id>NCT01951274</nct_id>
  </id_info>
  <brief_title>VPD-737 for Treatment of Chronic Pruritus</brief_title>
  <official_title>A Phase II Randomized, Double Blind, Parallel Group, Placebo-Controlled Dose Finding and Efficacy Study of VPD-737 in the Treatment of Subjects With Chronic Pruritus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tigercat Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tigercat Pharma, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of a several doses of a novel treatment for chronic itch compared to placebo   for
      patients whose condition has not responded to other treatments
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The sensation of itch is transmitted to the brain through the nervous system   Several
      chemicals are involved in transmitting this signal   This trial of VPD 737 is intended to
      treat this condition by blocking one of the chemicals involved in the transmission of the
      itch signal  This is an oral drug administered once daily  It has been used in other trials
      and has shown to be safe at the doses used in this trial   The trial will involve once daily
      pills for 6 weeks.   Subject will be asked to fill out questionnaires both electronically
      and on paper during the study period   Patients will also be monitored for safety and will
      have blood taken for testing and several points during the trial   Overall participation
      will last about 12 weeks
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Verbal Response Scale</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Chronic Pruritus</condition>
  <arm_group>
    <arm_group_label>0.25 mg VPD-737</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25 mg of VPD-737 daily by mouth for 42 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg VPD-737</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg VPD-737 taken daily by mouth for 42 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg VPD-737</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg tablets of VPD-737 to be taken daily by mouth for 42 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo tablets to be taken daily by mouth for 42 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VPD-737</intervention_name>
    <description>NK1 Receptor Antagonist</description>
    <arm_group_label>0.25 mg VPD-737</arm_group_label>
    <arm_group_label>1 mg VPD-737</arm_group_label>
    <arm_group_label>5 mg VPD-737</arm_group_label>
    <other_name>Serlopitant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of chronic pruritus and unresponsive to current therapies

        Exclusion Criteria:

          -  Have chronic liver or renal disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward F Schnipper, MD</last_name>
    <role>Study Director</role>
    <affiliation>Acting Chief Medical Officer, Tigercat Pharma, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Dunn</last_name>
    <phone>201-587-0500</phone>
    <phone_ext>3391</phone_ext>
  </overall_contact>
  <location>
    <facility>
      <name>Suzanne Bruce and Associates, P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>December 4, 2013</lastchanged_date>
  <firstreceived_date>July 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
